安卡拉痘苗病毒变异株可保护猕猴免受猴痘病毒的呼吸道攻击。
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
作者信息
Stittelaar Koert J, van Amerongen Geert, Kondova Ivanela, Kuiken Thijs, van Lavieren Rob F, Pistoor Frank H M, Niesters Hubert G M, van Doornum Gerard, van der Zeijst Ben A M, Mateo Luis, Chaplin Paul J, Osterhaus Albert D M E
机构信息
Department of Virology, Erasmus MC, Building Hoboken, Room Ee 17.26, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands.
出版信息
J Virol. 2005 Jun;79(12):7845-51. doi: 10.1128/JVI.79.12.7845-7851.2005.
Abstract
The use of classical smallpox vaccines based on vaccinia virus (VV) is associated with severe complications in both naive and immune individuals. Modified vaccinia virus Ankara (MVA), a highly attenuated replication-deficient strain of VV, has been proven to be safe in humans and immunocompromised animals, and its efficacy against smallpox is currently being addressed. Here we directly compare the efficacies of MVA alone and in combination with classical VV-based vaccines in a cynomolgus macaque monkeypox model. The MVA-based smallpox vaccine protected macaques against a lethal respiratory challenge with monkeypox virus and is therefore an important candidate for the protection of humans against smallpox.
摘要
基于痘苗病毒（VV）的传统天花疫苗在初次接种者和免疫个体中均会引发严重并发症。安卡拉改良痘苗病毒（MVA）是一种高度减毒的、复制缺陷型痘苗病毒株，已被证明在人类和免疫功能低下的动物中是安全的，目前正在研究其对天花的疗效。在此，我们在食蟹猴猴痘模型中直接比较了单独使用MVA以及将其与传统的基于VV的疫苗联合使用的效果。基于MVA的天花疫苗可保护猕猴免受猴痘病毒的致命性呼吸道攻击，因此是保护人类免受天花侵害的重要候选疫苗。
相似文献
1
Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.
J Virol. 2005 Jun;79(12):7845-51. doi: 10.1128/JVI.79.12.7845-7851.2005.
2
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
Nature. 2004 Mar 11;428(6979):182-5. doi: 10.1038/nature02331.
3
Smallpox vaccine does not protect macaques with AIDS from a lethal monkeypox virus challenge.
J Infect Dis. 2005 Feb 1;191(3):372-81. doi: 10.1086/427265. Epub 2005 Jan 4.
4
Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Virology. 2005 Sep 1;339(2):164-75. doi: 10.1016/j.virol.2005.06.002.
5
Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.
J Virol. 2004 May;78(9):4433-43. doi: 10.1128/jvi.78.9.4433-4443.2004.
6
Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques.
Vaccine. 2011 Dec 6;29(52):9684-90. doi: 10.1016/j.vaccine.2011.09.135. Epub 2011 Oct 12.
7
Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Nature. 2006 Feb 9;439(7077):745-8. doi: 10.1038/nature04295. Epub 2005 Dec 11.
8
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10889-94. doi: 10.1073/pnas.0804985105. Epub 2008 Aug 4.
9
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. doi: 10.1073/pnas.0401165101. Epub 2004 Mar 11.
10
Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
J Virol. 2004 Nov;78(22):12471-9. doi: 10.1128/JVI.78.22.12471-12479.2004.
引用本文的文献
1
Tiantan vaccinia virus-based vaccine with promising safety provides sustained protection against mpox in non-human primates.
Nat Commun. 2025 Aug 5;16(1):7183. doi: 10.1038/s41467-025-62594-0.
2
A new attenuated and highly immunogenic orthopoxvirus vaccine protects against mpox in mice and macaques.
NPJ Vaccines. 2025 Jul 1;10(1):134. doi: 10.1038/s41541-025-01193-y.
3
Exploring monkeypox virus antibody levels: insights from human immunological research.
Virol J. 2025 May 31;22(1):175. doi: 10.1186/s12985-025-02748-0.
4
Mpox Virus as a Global Public Health Emergency: A Scoping Review.
Can J Infect Dis Med Microbiol. 2025 Jan 22;2025:6683501. doi: 10.1155/cjid/6683501. eCollection 2025.
5
Current advances and challenges in mpox vaccine development: a global landscape.
Ther Adv Vaccines Immunother. 2025 Jan 27;13:25151355251314339. doi: 10.1177/25151355251314339. eCollection 2025.
6
Smallpox vaccination campaigns resulted in age-associated population cross-immunity against monkeypox virus.
J Gen Virol. 2024 Jun;105(6). doi: 10.1099/jgv.0.001999.
7
Poxviridae Pneumonia.
Adv Exp Med Biol. 2024;1451:183-204. doi: 10.1007/978-3-031-57165-7_12.
8
Experimental inoculation of pigs with monkeypox virus results in productive infection and transmission to sentinels.
Emerg Microbes Infect. 2024 Dec;13(1):2352434. doi: 10.1080/22221751.2024.2352434. Epub 2024 Jun 11.
9
Designing a smallpox B-cell and T-cell multi-epitope subunit vaccine using a comprehensive immunoinformatics approach.
Microbiol Spectr. 2024 Jun 4;12(6):e0046524. doi: 10.1128/spectrum.00465-24. Epub 2024 May 3.
10
Monkeypox: Immune response, vaccination and preventive efforts.
Narra J. 2022 Dec;2(3):e90. doi: 10.52225/narra.v2i3.90. Epub 2022 Oct 22.
本文引用的文献
1
Dendritic cells from mice neonatally vaccinated with modified vaccinia virus Ankara transfer resistance against herpes simplex virus type I to naive one-week-old mice.
J Immunol. 2004 May 15;172(10):6304-12. doi: 10.4049/jimmunol.172.10.6304.
2
Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Proc Natl Acad Sci U S A. 2004 Mar 30;101(13):4590-5. doi: 10.1073/pnas.0401165101. Epub 2004 Mar 11.
3
Zoonotic poxvirus infections in humans.
Curr Opin Infect Dis. 2004 Apr;17(2):81-9. doi: 10.1097/00001432-200404000-00003.
4
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox.
Nature. 2004 Mar 11;428(6979):182-5. doi: 10.1038/nature02331.
5
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome.
Lancet. 2003 Jul 26;362(9380):263-70. doi: 10.1016/S0140-6736(03)13967-0.
6
Separate worlds set to collide: smallpox, vaccinia virus vaccination, and human immunodeficiency virus and acquired immunodeficiency syndrome.
Clin Infect Dis. 2003 Aug 1;37(3):426-32. doi: 10.1086/375823. Epub 2003 Jul 22.
7
US military smallpox vaccination program experience.
JAMA. 2003 Jun 25;289(24):3278-82. doi: 10.1001/jama.289.24.3278.
8
Smallpox vaccination and bioterrorism with pox viruses.
Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):423-30. doi: 10.1016/S0147-9571(03)00025-0.
9
Progressive vaccinia.
Clin Infect Dis. 2003 Mar 15;36(6):766-74. doi: 10.1086/374244. Epub 2003 Feb 20.
10
Development of vaccines for bio-warfare agents.
Dev Biol (Basel). 2002;110:99-105.
Zotero 插件